FDA Asks, Gets Answers on Reducing Opioid Epidemic

Posted 14 Oct, 2017

The prevalence and consequences of opioid use disorder can be reduced without preventing patients with pain from receiving necessary opioid analgesics, according to a consensus report from the National Academies of Sciences, Engineering, and Medicine requested by the FDA.

The report, issued July 13, distinguishes its findings and recommendations from previous assessments and interventions by noting that most measures have focused on curtailing access—with marginal success—while failing to address the requirement of opioids for pain control.

“It should be emphasized, however, that none of these studies investigate the impact of reduced access on the well-being of individuals suffering from pain whose access to opioids was curtailed,” the report stated in a summary of strategies for restricting supply.

Please click the link below to read further:

Have a question? Or would like to book in with us?

Get in Touch

Common Conditions
that we Treat Everyday

View All Conditions

Latest from the Blog

Posted 07 Feb, 2019

Stellate Ganglion Block a Potential Lifesaver in Severe PTSD

Case reports are mounting of immediate, durable, and significant relief of severe refractory symptoms of posttraumatic stress disorder (PTSD), according to an anesthesiologist who has seen the benefits firsthand. Stellate ganglion blockade (SGB) “seems to significantly improve PTSD symptoms as well as significant...
Posted 25 Jan, 2019

CGRP Antagonists: A new era for migraine treatment

Migraine is a common medical condition, affecting as many as 37 million people in the US. It is considered a systemic illness, not just a headache. Recent research has demonstrated that changes may begin to occur in the brain as long as 24 hours before migraine symptoms begin. Many patients have a severe throbbing head...